Increasing Incidence Of Diabetes Will Drive The Metabolic Disorder Drugs Market

26 Feb, 2020

Metabolic disorder drugs will be the pharmaceutical drugs market’s fastest growing segment to 2021, growing at an annual rate of 9.05%. Metabolic disorder drugs also had the highest compound annual growth rate (CAGR) of 11.59% during 2013-2017. The rapid growth in the historic period can be attributed to the growing diabetic population worldwide, and increasing academia-industry collaborations to develop new drugs for the treatment of metabolic disorders. The metabolic disorder drugs market will continue to be driven by rapid growth in the number of diabetic patients in the forecast period, which, according to the World Health Organization, is expected to be the world’s seventh leading cause of death in 2030.

The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Major drugs used in the treatment of metabolic diseases are insulin, methimazole, and calcimimetics. The metabolic disorders drugs market is segmented into anti-diabetics’ drugs, anti-thyroid drugs, and others (hyperparathyroidism, hypopituitarism, hypoadrenalism).

The global pharmaceutical drugs market is segmented based on the targeted therapeutic area. The therapeutic areas that are targeted by the drugs for treatment include musculoskeletal drugs, cardiovascular drugs, oncology drugs, anti-infective drugs, metabolic disorders drugs, central nervous system drugs, genito-urinary drugs, respiratory diseases drugs, gastrointestinal drugs, hematology drugs, dermatology drugs, and ophthalmology drugs. The second fastest growing segment among these will be the musculoskeletal disorders drugs market, at 8% annual growth rate to 2021. This growth is contributed to increase in healthcare awareness, increase in number of surgical operations, and prevalence of musculoskeletal disorders such as fibromyalgia, rheumatoid arthritis, and osteoarthritis around the world. Increasing number of road accidents and workplace injuries will also drive the market for musculoskeletal disorders drugs.

The development of new drugs and drug delivery technologies is an emerging trend in the metabolic disorder drugs and musculoskeletal disorder drugs market. Drug manufacturers are developing various anti-diabetic drugs for type-2 diabetes treatment. Type 2 diabetes is noninsulin-dependent diabetes that affects sugar (glucose) metabolism of the patient by either resisting or restricting the effects of insulin. In July 2017, researchers at the University of California found that Amlexanox, a repurposed asthma drug with anti-inflammatory and anti-allergic properties, can improve blood sugar levels in type 2 diabetic patients.

In the musculoskeletal drugs market, the introduction of advanced pain free drug delivery technologies is promoting the use of musculoskeletal drugs. Drug delivery products such as intrathecal pumps are being used to deliver muscle relaxants such as baclofen directly into the spinal cord to provide instant relief. Intra-Articular drug delivery systems are also widely being used to administer medicines to treat arthritis.